The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03860935
Recruitment Status : Completed
First Posted : March 4, 2019
Last Update Posted : July 10, 2023
Information provided by (Responsible Party):
Eidos Therapeutics, a BridgeBio company

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : May 11, 2023
Actual Study Completion Date : May 11, 2023
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 May 10, 2024
June 4, 2024 Submission with QC Comments
2 June 5, 2024